ESPOO, Finland–(BUSINESS WIRE)–Basware (Nasdaq: BAS1V) has launched an updated developer website, which contains all Basware APIs – P2P and Network – in one site. From invoice sending and receiving to master data imports and invoice transfer, the enhanced site documents 20+ APIs so that customers, developers, partners and third-party system integrators can develop integrations faster and with less effort.

“We believe open APIs form a foundation for building a holistic ecosystem,” says Dr. Matt Lees, Director, Platform Solutions at Basware. “API usage has been growing steadily and we see that our customers are starting to adopt APIs at an increasing speed. Basware offers flexibility by providing several integration methods as well as integration services and in-house delivery competencies. We will continue to expand the capabilities of our APIs and introduce more process APIs and some self-serving capabilities, such as a monitoring API, in the future.”

Easily accessible via

Read More

SARASOTA, Fla., Sept. 23, 2020 /PRNewswire/ — Revcontent, a leading content marketing and discovery platform, today announced strong revenue growth and new premium publisher clients including Barstool Sports,,, McClatchy, Nexstar Digital and Salon. Despite the devastating impact of COVID-19 on the global economy, Revcontent has continued to gain traction as it delivers new revenue and growth opportunities to digital publishers around the world.

The company recently appointed Richard Marques as chief executive officer. Marques has helped lead the company’s growth and strategy since its founding in 2013. Prior to his appointment as CEO, Marques served as both chief marketing officer and chief operating officer. Under Marques’ leadership, Revcontent has been consistently winning in head-to-head A/B tests against the leading competitors in the space. Marques has been integral in growing the company’s premium publisher base, including new exclusive partnerships with Nexstar Digital, LA Times, Salon, Barstool Sports, increasing

Read More

(Reuters) – Gilead Sciences Inc will acquire biotech company Immunomedics Inc for $21 billion, a move that will strengthen its cancer portfolio by gaining access to a promising drug, the two companies said in a joint statement on Sunday.

The deal will give Gilead access to Immunomedics’ breast cancer treatment drug Trodelvy, which was granted an accelerated FDA approval in April for an aggressive and tough to treat type of breast cancer.

Gilead said it would issue a tender offer to buy all the outstanding shares of Immunomedics for $88 per share, representing a premium of about 108% over their last closing price of $42.25 on Friday.

“This acquisition represents significant progress in Gilead’s work to build a strong and diverse oncology portfolio,” Gilead Chief Executive Officer Daniel O’Day said in a statement. “Trodelvy is an approved, transformational medicine for a form of cancer that is particularly challenging to treat.

Read More

A man counting gold bars.

Akos Stiller | Bloomberg | Getty Images

Gold prices fell to a near one-week low on Thursday, as positive economic data from the United States elevated hopes for a quick economic recovery, denting the safe-haven metal’s appeal.

Spot gold was down by 0.6% to $1,930.58 per ounce, having earlier fallen to $1,926.99. U.S. gold futures dropped 1.7% to settle at $1,944.70.

A drop in jobless claims and positive manufacturing data early in the week are taking some shine off gold, said David Meger, director of metals trading at High Ridge Futures.

U.S. weekly jobless claims fell below 1 million last week for the second time since the pandemic started, but did not signal a strong recovery in the labor market.

Data this week boosted optimism about a steady recovery as new orders for U.S.-made goods increased more than expected in July, while U.S. manufacturing data

Read More

BL Research Bureau

Reliance Retail’s shopping basket got a major fill over the weekend – with the acquisition of the retail & wholesale business and the logistics & warehousing business of the debt-laden Future Group for ₹24,713 crore. This is the second buy by Reliance Retail in a fortnight, following its acquisition of digital pharma marketplace Netmeds for ₹620 crore.

More buys could follow with Reliance Retail seeming to have embarked on an acquisitions-driven growth strategy. The company is said to be in talks to acquire stakes in online furniture company Urban Ladder, online grocer Milkbasket and lingerie brand Zivame. This approach seems similar to the ‘string of pearls’ strategy adopted by RIL in its digital business through a host of acquisitions such as Haptik, Embibe and Reverie to build a broader digital ecosystem.


Reliance Retail could also integrate acquisitions such as the Future Group’s acquired business and Netmeds with

Read More